StockData
Halozyme Therapeutics, Inc. logo

Halozyme Therapeutics, Inc. (HALO) stock

HALONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 13/3037% above fair value
$95.80−0.17 (-0.18%)

Close on Nov 18, 2026Market cap $10.87BP/E 28.3Yield –

Halozyme Therapeutics pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

Halozyme Therapeutics's pe ratio was 30.0× on Nov 11, 2026, against 15.0× a year earlier. Over the last 5 years it ranged from 12.4× to 38.6×, with a median of 19.4×.

PE Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 202630.0×+15.8
2025Dec 31, 202514.2×−1.7
2024Dec 31, 202415.8×−3.9
2023Dec 29, 202319.8×−18.4
2022Dec 30, 202238.2×+23.8
2021Dec 31, 202114.4×−252.5
2020Dec 31, 2020266.9×+266.9
2019Jan 31, 20190.0×+0.0
2018Dec 31, 20180.0×–

More Halozyme Therapeutics figures

See a number that looks wrong?